Prosecution Insights
Prosecution Insights
17 pending office actions • 7 art units • 14 examiners • 0 of 17 (0%) have an AI response strategy ready • 17 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 7 (41%) |
| §112 only | 1 (6%) |
| Double-patenting + other | 5 (29%) |
| Multi-statute (no §101) | 4 (24%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAN DRUFF, SYDNEY | 2 | 55.6% | +30.6% |
| GALSTER, SAMUEL LEONARD | 2 | 52.3% | +41.7% |
| CANELLA, KAREN A | 2 | 62.2% | +32.8% |
| JUEDES, AMY E | 1 | 45.0% | +41.4% |
| LIU, TRACY | 1 | 54.5% | +27.0% |
| BASQUILL, SEAN M | 1 | 38.8% | +21.7% |
| ANTHOPOLOS, PETER | 1 | 57.2% | +59.0% |
| MILLER, DALE R | 1 | 62.4% | +17.4% |
| PETRASH, HILARY ANN | 1 | 63.9% | +53.5% |
| LU, CHENG | 1 | 53.7% | +66.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263124 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | GALSTER, SAMUEL LEONARD | 6d |
| 18025896 | A Scoring Method for an Anti-HER2 Antibody-Drug Conjugate Therapy | LU, CHENG | 21d |
| 18549797 | NOVEL DEALKOXYPHENYLATION REACTION | MILLER, DALE R | 33d |
| 18561804 | HPV INFECTIOUS DISEASE VACCINE | ANTHOPOLOS, PETER | 46d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18767925 | METHOD FOR PRODUCING AN ANTI-LAG-3 ANTIBODY | JUEDES, AMY E | 45d overdue |
| 18263124 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | GALSTER, SAMUEL LEONARD | 6d |
| 18025896 | A Scoring Method for an Anti-HER2 Antibody-Drug Conjugate Therapy | LU, CHENG | 21d |
| 18367446 | METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE | VAN DRUFF, SYDNEY | 22d |
| 18252838 | COMPLEX OF BETA-GLUCAN AND NUCLEIC ACID HAVING CONTROLLED PARTICLE SIZE | GALSTER, SAMUEL LEONARD | 22d |
| 17058838 | TREATMENT OF HER2-MUTATED CANCER BY ADMINISTERING ANTI-HER2 ANTIBODY-DRUG CONJUGATE | VAN DRUFF, SYDNEY | 27d |
| 18549797 | NOVEL DEALKOXYPHENYLATION REACTION | MILLER, DALE R | 33d |
| 18561804 | HPV INFECTIOUS DISEASE VACCINE | ANTHOPOLOS, PETER | 46d |
| Art Unit | Apps |
|---|---|
| 1643 | 5 |
| 1614 | 3 |
| 1693 | 3 |
| 1644 | 2 |
| 1642 | 2 |
| 1611 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18767925 | METHOD FOR PRODUCING AN ANTI-LAG-3 ANTIBODY | JUEDES, AMY E | 1644 | §112Other | Final Rejection | 45d overdue | Pending | Jul 09, 2024 |
| 18708875 | PHARMACEUTICAL COMPOSITION HAVING EXCELLENT DISSOLUTION PROPERTIES | LIU, TRACY | 1614 | §103 | Non-Final OA | 62d | Pending | May 09, 2024 |
| 18393228 | DRUG FOR RETINAL DEGENERATIVE DISEASE ASSOCIATED WITH PHOTORECEPTOR DEGENERATION | BASQUILL, SEAN M | 1614 | §103DP | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18561804 | HPV INFECTIOUS DISEASE VACCINE | ANTHOPOLOS, PETER | 1611 | §103§112Other | Non-Final OA | 46d | Pending | Nov 17, 2023 |
| 18367446 | METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE | VAN DRUFF, SYDNEY | 1643 | §103Other | Non-Final OA | 22d | Pending | Sep 12, 2023 |
| 18549797 | NOVEL DEALKOXYPHENYLATION REACTION | MILLER, DALE R | 1693 | §103§112Other | Non-Final OA | 33d | Pending | Sep 08, 2023 |
| 18263124 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | GALSTER, SAMUEL LEONARD | 1693 | §103§112 | Non-Final OA | 6d | Pending | Jul 26, 2023 |
| 18252838 | COMPLEX OF BETA-GLUCAN AND NUCLEIC ACID HAVING CONTROLLED PARTICLE SIZE | GALSTER, SAMUEL LEONARD | 1693 | §103 | Final Rejection | 22d | Pending | May 12, 2023 |
| 18036289 | COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY | PETRASH, HILARY ANN | 1644 | §102§103§112DP | Non-Final OA | — | Pending | May 10, 2023 |
| 18036290 | TREATMENT OF MESOTHELIOMA BY ADMINISTRATION OF ANTI-B7-H3 ANTIBODY-DRUG CONJUGATE | CANELLA, KAREN A | 1643 | §103§112DP | Final Rejection | — | Pending | May 10, 2023 |
| 18025896 | A Scoring Method for an Anti-HER2 Antibody-Drug Conjugate Therapy | LU, CHENG | 1642 | §103§112Other | Non-Final OA | 21d | Pending | Mar 11, 2023 |
| 17787760 | FILM-COATED TABLETS HAVING SMOOTH SURFACE | KNIGHT, SAMANTHA JO | 1614 | §103Other | Final Rejection | 32d overdue | Pending | Jun 21, 2022 |
| 17612765 | DOSAGE OF AN ANTIBODY-DRUG CONJUGATE | DARPOLOR, JOSEPHINE KEBBEH | 1642 | §103DPOther | Non-Final OA | — | Pending | Nov 19, 2021 |
| 17458225 | METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE | CANELLA, KAREN A | 1643 | §103Other | Non-Final OA | — | Pending | Aug 26, 2021 |
| 17312084 | COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH PARP INHIBITOR | SKOKO III, JOHN JOSEPH | 1643 | §103Other | Final Rejection | 54d | Pending | Jun 09, 2021 |
| 17058838 | TREATMENT OF HER2-MUTATED CANCER BY ADMINISTERING ANTI-HER2 ANTIBODY-DRUG CONJUGATE | VAN DRUFF, SYDNEY | 1643 | §103Other | Final Rejection | 27d | Pending | Nov 25, 2020 |
| 16640914 | ANTIBODY-DRUG CONJUGATE PREPARATION AND LYOPHILIZATION FOR SAME | KIM, YUNSOO | 1641 | §103DP | Final Rejection | 81d overdue | Pending | Feb 21, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial